LYON, France–(BUSINESS WIRE)–Regulatory News:

Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company specializing in the development of innovative formulations of proteins and peptides for the treatment of diabetes and other metabolic diseases announced today its participation to the following investors events:

  • ODDO BHF Forum (January 9 and 10, 2023, virtual)

During these professional meetings with the financial community, through “one-to-one” or “one-to-few” formats, Adocia’s management will review Adocia’s news and outlook for 2023.

  • JPM 2023 – 41st Annual Healthcare Meeting (January 9 – 12, 2023, in San Francisco)

Adocia will attend at the JP Morgan 2023 and will meet with investors and leaders in healthcare.

  • Biotech Showcase (January 9 – 11, 2023, in San Francisco)

Olivier Soula, Adocia Deputy CEO, will present “Innovation in diabetes and “diabesity”, from protein delivery to cell therapy”, at the Biotech Showcase on January 10th.

During this conference dedicated to investors, Olivier Soula will review the progress of Adocia’s flagship clinical programs in diabetes (BioChaperone® Lispro and M1Pram) and present the latest results of the AdoShell® technology in cell therapy.

About Adocia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The company has a broad portfolio of drug candidates based on four proprietary technology platforms:

1) The BioChaperone® technology for the development of new generation insulins and products combining insulins with other classes of hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with a first application in pancreatic cells transplantation; 4) AdoGel®, a long-acting drug delivery platform.

Adocia holds more than 25 patent families.

Based in Lyon, the company has about 100 employees. Adocia is listed on the regulated market of EuronextTM Paris (Euronext: ADOC; ISIN: FR0011184241).


This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those which are set forth in the “Risk Factors” section of the universal registration document that was filed with the French Autorité des marchés financiers on April 21, 2022 (a copy of which is available at, in particular uncertainties that are linked to research and development, future clinical data, analyses, and the evolution of the economic context, the financial markets and the markets in which Adocia operates.

The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia as of this day. The occurrence of all or part of such risks could cause that actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.


Gérard Soula
+33 (0)4 72 610 610

Ulysse Communication
Adocia Press and Investors Relations

Pierre-Louis Germain
Margaux Puech Pays d’Alissac
Bruno Arabian
+ 33 (0)6 64 79 97 51